Glioblastoma multiforme-reactive antibodies and methods of use thereof
AssigneeThe Regents of the University of California
InventorsBin LIU, James D. MARKS, Xiaodong ZHU, Scott BIDLINGMAIER
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.
Claims23
An isolated antibody that binds specifically to glioblastoma multiforme (GBM) tumor sphere cells, wherein the anti-GBM antibody comprises an antigen binding site that comprises:
- a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO:
- 67, (ii) CDR-H2 comprising SEQ ID NO:
- 69, and (iii) CDR-H3 comprising SEQ ID NO 71, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO:
- 75, (v) CDR-L2 comprising SEQ ID NO 77, and (vi) CDR-L3 comprising SEQ ID NO 79.
2-5. (canceled)
A method for treating a cancer patient, comprising:
- A) providing a composition comprising an anti-GBM antibody comprising an antigen binding site that comprises
- a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO:
- 67, (ii) CDR-H2 comprising SEQ ID NO:
- 69, and (iii) CDR-H3 comprising SEQ ID NO:
- 71, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO:
- 75, (v) CDR L2 comprising SEQ ID NO:
- 77, and (vi) CDR-L3 comprising SEQ ID NO:
- 79;
- and
- B) administering to the patient the composition in an amount effective to inhibit proliferation of tumor cells of the patient.
Dependencies are inferred from the claim text.